PCVX

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

34.900

Open

32.720

VWAP

34.16

Vol

1.27M

Mkt Cap

4.48B

Low

32.270

Amount

43.53M

EV/EBITDA(TTM)

Total Shares

108.80M

2.35B

EV/OCF(TTM)

P/S(TTM)

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

10 Analyst Rating

257.00% Upside

Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 124.13 USD with a low forecast of 65.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

257.00% Upside

Current: 34.770

Low

65.00

Averages

124.13

High

160.00

257.00% Upside

Current: 34.770

Low

65.00

Averages

124.13

High

160.00

Cantor Fitzgerald

Carter Gould

Buy

Initiates

n/a

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

n/a

2025-04-22

Initiates

Buy

Reason

Cantor Fitzgerald analyst Carter Gould initiated coverage of Vaxcyte with an Overweight rating.

Needham

Joseph Stringer

Strong Buy

Reiterates

$90

2025-04-08

Reason

Needham

Joseph Stringer

Price Target

$90

2025-04-08

Reiterates

Strong Buy

Reason

Needham lowered the firm's price target on Vaxcyte to $90 from $140 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 trial evaluating pneumococcal conjugate vaccine VAX-24 in infants. Post-dose 3 data showed that the mid-dose hit non-inferiority on 20 of 24 serotypes, which fit the firm's "at minimum" scenario of 4 ST misses, but was below "relatively high Street expectations" as investors were likely looking for 0-2 ST misses for PD3 and PD4, the analyst says. It is now "clear that some dose optimization on individual serotypes is needed for VAX-24," which introduces a measure of uncertainty, says the analyst, who cites increased macro and development risk for the firm's lowered target.

Needham

Joseph Stringer

Strong Buy

Maintains

$140 → $90

2025-04-01

Reason

Needham

Joseph Stringer

Price Target

$140 → $90

2025-04-01

Maintains

Strong Buy

Reason

B of A Securities

Jason Gerberry

Strong Buy

Maintains

$157 → $137

2025-04-01

Reason

B of A Securities

Jason Gerberry

Price Target

$157 → $137

2025-04-01

Maintains

Strong Buy

Reason

Goldman Sachs

Chris Shibutani

Strong Buy

Maintains

$138 → $100

2025-04-01

Reason

Goldman Sachs

Chris Shibutani

Price Target

$138 → $100

2025-04-01

Maintains

Strong Buy

Reason

Guggenheim

Seamus Fernandez

Strong Buy

Reiterates

$160

2025-03-12

Reason

Guggenheim

Seamus Fernandez

Price Target

$160

2025-03-12

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vaxcyte Inc (PCVX.O) is -7.16, compared to its 5-year average forward P/E of -12.93. For a more detailed relative valuation and DCF analysis to assess Vaxcyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.93

Current PE

-7.16

Overvalued PE

-8.69

Undervalued PE

-17.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.95

Current EV/EBITDA

-4.45

Overvalued EV/EBITDA

-6.53

Undervalued EV/EBITDA

-17.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

795.58

Current PS

0.00

Overvalued PS

2077.27

Undervalued PS

-486.11